Ratings
0
Nobody has rated this yet. Be the first!
Works
3
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor
